Testosterone therapy for men who produce little to no hormones does not increase their risk of heart attack, according to a study published in the Annals of Pharmacology.
Testosterone use has skyrocketed in recent years, but the studies about its effects have yielded conflicting evidence. Although a large body of evidence found that testosterone therapy does not have any cardiovascular risks, recent studies have found an increased risk of heart attack. Researchers wanted to help definitively determine whether testosterone treatment has any cardiovascular risk.
To conduct the study, researchers compared Medicare records of 6,355 men who had at least one testosterone injection between 1997 and 2005 with 19,065 nontestosterone users. Testosterone-using patients received an average of 8.2 injections over the study period, with an average of 4.4 in the first year. Their results showed that testosterone therapy prescribed for hypergonadism was not associated with an increased risk of heart attack.
In fact, patients who had a higher probability of cardiovascular problems had a 30% lower rate of heart attacks than patients with the same probability of cardiovascular problems who were not receiving testosterone therapy.The study was limited to patients in the Houston area. Researchers noted that a large-scale, randomized trial is needed for more definitive evidence.
For men who produce little to no hormones, testosterone Tx does not increase heart attack risk.
Testosterone treatment prescribed for men whose bodies produce little or no hormones doesn’t increase the risk of heart attack, according to a Houston-area study that should ease fears of men with the condition. The study, conducted by researchers at the University of Texas Medical Branch at Galveston, rebuts recent research that suggested the steroid hormone may be hazardous to men’s cardiovascular health.
The research had stirred much concern among both doctors and patients because testosterone use has exploded in recent years. “Testosterone’s perceived risk and impact on patients has been in the news a lot lately,” said Jacques Baillargeon, a UTMB professor of epidemiology and the study’s lead author. “I hope this study brings some balance to the debate, that it’s weighed alongside all the evidence.”
Enjoying our content?
Thanks for visiting Renal & Urology News. We hope you’re enjoying the latest clinical news, full-length features, case studies, and more.
You’ve viewed {{metering-count}} of {{metering-total}} articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.
{{login-button}} {{register-button}}
Log in to continue reading this article.
Don’t miss out on today’s top content on Renal & Urology News. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Case Studies
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
{{login-button}} {{register-button}}
Want to read more?
Please login or register first to view this content.